Streptococcus pneumoniaeantibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)
نویسندگان
چکیده
منابع مشابه
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.
Immunoglobulins (IgG) as replacement therapy in primary antibody deficiencies can be given as intramuscular injections, or as intravenous or subcutaneous infusions. Our aims were to obtain information on the frequency of adverse systemic reactions during subcutaneous therapy, the occurrence and intensity of tissue reactions at the infusion sites, and serum IgG changes. Furthermore, we compared ...
متن کاملShift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®) has been developed and has replaced Vivaglobin® (SCIG 16%). An observational prospective multi-centric open-label study, with retrospective comparison was conducted ...
متن کاملPredictors of Intravenous Immunoglobulin (IVIG) Resistance in Children with Kawasaki Disease in Calabria Region, Italy
Background Kawasaki disease (KD) is the second most common childhood vasculitis and one of the main causes of acquired heart disease in children. Recent work focuses on the early diagnostic importance of those risk factors that indicate resistance to intravenous immunoglobulin (IVIG) treatment. The objectives of this study were to identify clinical, laboratory and/or instrumental factors that c...
متن کاملCost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
Background: Economic evaluation of subcutaneous immunoglobulin therapy (SCIG) is important, and it has recently been used for treatment of patients with primary immunodeficiency (PID) diseases, and can improve allocation of resources in health care systems. The present research aimed at providing an economic assessment of SCIG and IVIG (intravenous immunoglobulin therapy) adm...
متن کاملImplications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
Background A nurse shortage in Canada is contributing to large amounts of paid/unpaid overtime and increased laborrelated expenditures. Shifting PID/SID patients from hospital-based IVIg to less labor-intensive home-based SCIg can improve their quality of life and treatment satisfaction [1] and may improve efficient allocation of nurse staff. The objectives for this study were to estimate the r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical & Experimental Immunology
سال: 2015
ISSN: 0009-9104
DOI: 10.1111/cei.12665